WO2004017916A3 - Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition - Google Patents

Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition Download PDF

Info

Publication number
WO2004017916A3
WO2004017916A3 PCT/US2003/026427 US0326427W WO2004017916A3 WO 2004017916 A3 WO2004017916 A3 WO 2004017916A3 US 0326427 W US0326427 W US 0326427W WO 2004017916 A3 WO2004017916 A3 WO 2004017916A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
composition
transfer factor
element
therapeutic methods
cardiovascular therapy
Prior art date
Application number
PCT/US2003/026427
Other languages
French (fr)
Other versions
WO2004017916A2 (en )
Inventor
William J Hennen
Original Assignee
4Life Res Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A composition for use in cardiovascular therapy includes transfer factor. The transfer factor may be nonmammalian transfer factor, such as that derived from eggs, or mammalian transfer factor, such as that derived from colostrum. The composition may also include one or more of the following: an LDL receptor-binding element; a blood flow-enhancing element; a cholesterol reducing element; a fat oxidation prevention element, and an antioxidant. Treatment methods include enlisting the immune system of a subject receiving therapy to attack pathogens that cause inflammation of blood vessels or to otherwise reduce inflammation of blood vessels.
PCT/US2003/026427 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition WO2004017916A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US40535802 true 2002-08-22 2002-08-22
US60/405,358 2002-08-22

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2003265620A AU2003265620A8 (en) 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition

Publications (2)

Publication Number Publication Date
WO2004017916A2 true WO2004017916A2 (en) 2004-03-04
WO2004017916A3 true true WO2004017916A3 (en) 2004-10-14

Family

ID=31946861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/026427 WO2004017916A3 (en) 2002-08-22 2003-08-22 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition

Country Status (2)

Country Link
US (2) US7815943B2 (en)
WO (1) WO2004017916A3 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US6866868B1 (en) * 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US9028882B2 (en) 2005-05-02 2015-05-12 4Life Patents, Llc Nutraceutical gels
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
JP6121907B2 (en) 2010-11-23 2017-04-26 パンサリクス,インコーポレイティド Wide area, atypical, or composition for the treatment of clinical application of mixing and method
US20120177631A1 (en) * 2011-01-10 2012-07-12 Morteza Naghavi Composition for Health Promoting Compounds
US8815310B2 (en) * 2011-01-10 2014-08-26 Morteza Naghavi Compositions for boosting metabolism, assisting weight loss, and promoting cardiovascular health
US10004757B1 (en) 2017-09-22 2018-06-26 Nutri Vida, LLC Oral supplement

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816563A (en) * 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
JPH05508847A (en) * 1990-07-02 1993-12-09
DE69826253D1 (en) * 1997-03-20 2004-10-21 Coventry Group Ltd Dietary supplement for health kardiovasküläre
US6022901A (en) * 1998-05-13 2000-02-08 Pharmascience Inc. Administration of resveratrol to prevent or treat restenosis following coronary intervention
CA2357685A1 (en) * 2000-09-18 2002-03-18 Chisolm Biological Laboratory, Llc Transfer factor composition and process for producing same
US6468534B1 (en) * 2000-09-21 2002-10-22 4Life Research, Lc Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
US6693094B2 (en) * 2001-03-22 2004-02-17 Chrono Rx Llc Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes

Also Published As

Publication number Publication date Type
US20110033414A1 (en) 2011-02-10 application
US20040126432A1 (en) 2004-07-01 application
WO2004017916A2 (en) 2004-03-04 application
US7815943B2 (en) 2010-10-19 grant
US9849157B2 (en) 2017-12-26 grant

Similar Documents

Publication Publication Date Title
Cavallini et al. Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study
WO2004013172A3 (en) Fragments of beta-amyloid as targets for vaccination against alzheimer disease
Mavissakalian et al. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels.
JPS62249931A (en) Antibacterial composition
WO2004074457A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO1997049827A3 (en) Adenoviral mediated gene transfer in adipocytes and related implants
Hopman et al. The effect of an anti-G suit on the maximal performance of individuals with paraplegia
Dujovne et al. Fluvastatin administration of bedtime versus with the evening meal: A multicenter comparison of bioavailability, safety, and efficacy
Kränzlin Calcium supplementation, osteoporosis and cardiovascular disease
WO2003039270A1 (en) Antiobestic foods and drinks
WO2005038012A3 (en) Cartilage and bone repair and regeneration using postpartum-derived cells
Rubey et al. Clomipramine treatment of sexual preoccupation.
Federspil Ear epistheses as an alternative to autogenous reconstruction
CN1927164A (en) Skin antisenescence formulation containing catechin
CN103027117A (en) Milk beverage
Shema-Didi et al. Pomegranate juice intake attenuates the increase in oxidative stress induced by intravenous iron during hemodialysis
Javorková et al. Effect of polyphenolic compounds on the renal Na+, K+‐ATPase during development and persistence of hypertension in rats
Carrero et al. Nutritional therapy, phosphate control and renal protection
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
CN101862001A (en) Aloe nutritive beverage
Schettler et al. How to optimize lipoprotein apheresis treatment–a second look
CN1748552B (en) Health honey concentrated juice
CN1286475C (en) Chinese medicine for treating liver disease

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP